Inactive Instrument

News Inovio Pharmaceuticals Inc Nyse

Equities

US45773H1023

End-of-day quote Nyse Other stock markets
- ^USD	-

Apr. 16	Powell Comments, Middle East Tensions in Focus as US Equity Futures Gain Pre-Bell	MT
Apr. 16	Inovio Pharmaceuticals Shares Slump Pre-Bell After Pricing of $36 Million Offering of Common Stock, Warrants	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Powell Comments, Middle East Tensions in Focus as US Equity Futures Gain Pre-Bell	Apr. 16	MT
Inovio Pharmaceuticals Shares Slump Pre-Bell After Pricing of $36 Million Offering of Common Stock, Warrants	Apr. 16	MT
Top Premarket Decliners	Apr. 16	MT
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants	Apr. 15	PR
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine	Mar. 26	PR
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights	Mar. 07	AQ
Transcript : Inovio Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 06, 2024	Mar. 06
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024	Feb. 21	PR
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 07	PR
INOVIO Reports Inducement Grant Under Inducement Plan	Feb. 02	PR
Oppenheimer Upgrades Inovio Pharmaceuticals to Outperform From Perform, $4 Price Target	Jan. 25	MT
Reverse Split: 1 of 12	Jan. 24	FA
Transcript : Inovio Pharmaceuticals, Inc. - Special Call	Jan. 24
INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split	Jan. 23	PR
INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader	Jan. 22	PR
Inovio Pharmaceuticals, Coherus BioSciences to Collaborate on Potential Throat Cancer Treatment	Jan. 04	MT
INOVIO and Coherus Announces Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI?? (toripalimab-Ttzi)	Jan. 04	CI
Inovio Pharmaceuticals Plans BLA Submission for INO-3107 for Recurrent Respiratory Papillomatosis Treatment	Jan. 03	MT
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program	Jan. 03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Inovio Pharmaceuticals Inc Nyse

Equities

US45773H1023

Summary

Filters